Arcutis (ARQT) Director Howard G. Welgus Exercises Options, Sells Shares

What Happened
Howard G. Welgus, a director of Arcutis Biotherapeutics (ARQT), exercised vested stock options on September 15, 2026 to acquire a total of 4,096 shares at strike prices of $6.52, $7.51 and $8.63 (total cash cost $32,475). On the same date he sold 4,730 shares in an open-market transaction at $24.18 per share, receiving $114,371. The filing also shows corresponding derivative-conversion lines reported at $0, reflecting the conversion of options into shares.

Key Details

• Transaction date: 2026-09-15; Form 4 filed 2026-09-17 (appears timely).
• Options exercised (acquired): 822 @ $6.52 ($5,361); 1,019 @ $7.51 ($7,653); 2,255 @ $8.63 ($19,461) — total 4,096 shares, $32,475 cash cost.
• Open-market sale (disposed): 4,730 shares @ $24.18 = $114,371 proceeds.
• Derivative disposition lines reported at $0 reflect conversion of options into shares.
• Footnotes: transaction was made under a 10b5-1 trading plan adopted March 13, 2026 (plan ends June 15, 2027); the options exercised were fully vested.
• Shares owned after the transactions: not disclosed in the provided filing details.

Context

• This was an exercise of vested options followed by an open-market sale of shares. That sequence commonly reflects a cashless or partial sell-to-cover approach (exercise + immediate/near-immediate sale), but the filing itself does not state the holder’s motive.
• The use of a 10b5-1 plan means the trades were made under a pre-established plan, which can limit the extent to which the sales reflect current views on the company.
• Purchases (exercises) and sales are both reported; retail investors often view purchases as a stronger positive signal, while planned sales under 10b5-1 are often routine.